BioSig Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Core Viewpoint - BioSig Technologies, Inc. has regained compliance with Nasdaq's minimum bid price requirement, indicating a positive development for the company's stock status [1][2]. Company Overview - BioSig Technologies is a medical technology company focused on enhancing intra-cardiac signal visualization, particularly in heart rhythms, through innovative software solutions [3]. - The company's FDA 510(k) cleared PURE EP™ Platform offers superior real-time signal visualization, improving the efficiency and efficacy of cardiac ablation procedures [4]. Compliance Achievement - To regain compliance, BioSig's common stock needed to maintain a minimum closing bid price of $1.00 for at least 10 consecutive business days, which was achieved as of November 13, 2024 [2]. - Nasdaq has closed the prior bid price deficiency matter, confirming the company's compliance status [2]. Leadership Statement - The CEO of BioSig expressed gratitude for the support received during the relisting process and emphasized the company's commitment to increasing shareholder value [3].